OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.25
+7.14%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +11.9%
- EBIT
- +13.4%
- EPS
- +33.3%
- Free cash flow
- +18.9%
- Operating cash flow
- +18.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -14.7%
- EPS
- +61.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -13.5%
- EBIT
- -15.7%
- Net income
- -13.0%
- EPS
- -11.4%
- Free cash flow
- -1.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026